Experimental drug for rare inflammatory disease shows early promise but trial cut short

NCT ID NCT04918147

Terminated Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested elotuzumab, a drug used for multiple myeloma, in people with active IgG4-related disease (IgG4-RD), a rare condition causing inflammation and organ damage. The trial was small (only 8 participants) and was terminated early, so it is unclear if the drug is safe or effective. Participants received either elotuzumab plus prednisone or a placebo plus prednisone, and the main goal was to check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: elotuzumab (a monoclonal antibody)
What this could lead to: If it works, this could point toward a new treatment option for IgG4-related disease, reducing reliance on steroids.
What could go wrong: This trial was terminated early with only 8 participants enrolled, so results are very limited. It is too early to know if elotuzumab is safe or effective for this condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IGG4-RD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Immunoglobulin G4-Related Disease immunoglobulin G4-related sclerosing disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IGG4-RD IGG4-RELATED DISEASE

Contacts and locations

Locations

Emory Healthcare

Atlanta, Georgia, 30322, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mayo Clinic: Pulmonary and Critical Care Medicine

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.